AI-powered search
AI-powered search

Live Evaluations

IL-17 vs. IL-23 Inhibitors for Psoriasis: The Great Debate


IL-17 vs. IL-23 Inhibitors for Psoriasis: The Great Debate


This activity is supported by an educational grant from SUN Pharma.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Overview the key data on the IL-17 and IL-23 classes of biologics

  • Compare and contrast IL-17 and IL-23 biologic therapies based on clinical trial and real-world data

  • Categorize which biologic agents may be more appropriate for specific patient populations based on demographics, co-morbidities and medical history

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
April Armstrong, MD, MPH

Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Andrew Blauvelt, MD, MBA

Oregon Medical Research Center
Portland, OR

Alice Gottlieb, MD, PhD

Clinical Professor and Medical Director
Department of Dermatology
Mount Sinai Beth Israel Hospital
New York, NY

Mark Lebwohl, MD

Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Bruce Strober, MD, PhD

Clinical Professor of Dermatology
Yale University School of Medicine
New Haven, CT

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

Disclosures are as follows:

April W. Armstrong, MD, MPH

Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen 

Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel 

Andrew Blauvelt, MD, MBA

Grant/Research Support: AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte Consultant: AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Thera Speakers’ Bureau or Honoraria: AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Regeneron, Sanofi, and UCB

Alice B. Gottlieb, MD, PhD

Grant/Research Support: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai

Speakers’ Bureau or Honoraria: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project);

Other Financial Benefit: XBIOTECH stock options for a Rheumatoid Arthritis Project.  

Mark Lebwohl, MD

Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.

Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.

Bruce E. Strober, MD, PhD

Consultant: AbbVie, Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol-Myers-Squibb, Connect Biopharma, Dermavant, EPI Health, Evelo Biosciences, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Pfizer, UCB Pharma, Sun Pharma, Regeneron, Sanofi-Genzyme, Union Therapeutics, Ventyxbio, vTv Therapeutics

Speakers’ Bureau or Honoraria: AbbVie, Eli Lilly, Incyte, Janssen, Regeneron, Sanofi-Genzyme                                

Scientific Co-Director (consulting fee): CorEvitas (formerly Corrona) Psoriasis Registry

Investigator: Dermavant, AbbVie, CorEvitas Psoriasis Registry, Dermira, Cara, Novartis

Editor-in-Chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis
Ownership Interest: Connect Biopharma

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved